Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 87.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,960 shares of the company's stock after selling 79,939 shares during the quarter. Jane Street Group LLC's holdings in Evolus were worth $132,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EOLS. KBC Group NV acquired a new stake in shares of Evolus during the 4th quarter worth approximately $49,000. Rhumbline Advisers grew its stake in shares of Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after purchasing an additional 1,762 shares during the period. Principal Financial Group Inc. grew its stake in shares of Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after purchasing an additional 2,989 shares during the period. Rice Hall James & Associates LLC grew its stake in shares of Evolus by 4.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock worth $10,469,000 after purchasing an additional 43,381 shares during the period. Finally, IFP Advisors Inc grew its stake in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the period. Institutional investors and hedge funds own 90.69% of the company's stock.

Insider Buying and Selling at Evolus

In other news, CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the transaction, the chief financial officer now owns 173,583 shares in the company, valued at $2,301,710.58. The trade was a 4.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. This represents a 7.15% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 86,241 shares of company stock worth $1,048,666. Corporate insiders own 5.90% of the company's stock.

Evolus Price Performance

Evolus stock opened at $10.04 on Friday. The company's fifty day moving average price is $10.39 and its 200 day moving average price is $11.89. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82. The stock has a market capitalization of $647.34 million, a P/E ratio of -11.03 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on EOLS shares. Barclays raised their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. BTIG Research started coverage on shares of Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.